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Background: Most patients hospitalized with acute decompensated heart failure (ADHF) present through the emergency department (ED). Prior 
studies suggest that ED treatment delay may be associated with an increased risk of in-hospital mortality; however, the association with 30-day 
mortality and re-admission rates remains uncertain. We examined the association of time to first intravenous (IV) HF therapy with in-hospital and 
30-day outcomes.
methods: Using the ADHERE Registry Emergency Module (ADHERE-EM) linked to Medicare claims data, we identified patients aged ≥65 years 
old admitted for ADHF (index admission) who were enrolled in fee-for-service Medicare. Patients who did not receive IV HF therapy (e.g. diuretics, 
vasodilators and/ or inotropes) during index admission were excluded. Cox proportional hazard models were used to assess the association of time 
to first IV HF therapy with 30-day all-cause mortality and or re-admission. Generalized linear mixed models were used to examine the association of 
time to first IV HF therapy with in-hospital mortality and length of stay.
results: 6,971 patients were included in this analysis. Most patients received the first IV HF therapy promptly, with median time to treatment of 
2.3 hours (IQR 1.1, 4.4). The cumulative incidence of 30-day all-cause mortality or re-admission did not differ by quartile of time to treatment. In the 
adjusted Cox model, time to first IV HF therapy was not associated with an increased risk of 30-day all-cause mortality or re-admission. Confirming 
earlier studies, time to first IV HF therapy had a statistically significant but modest clinical impact on in-hospital mortality rate (adjusted OR 1.01 
per hour delay; 95% CI 1.00, 1.02; P=0.001) and length of stay (adjusted estimate 0.057 day per hour delay; 95% CI 0.047, 0.066; P<0.0001).
conclusions: Among older patients presenting to an ED with ADHF, most received prompt IV HF therapy. Increased time to administration of first IV 
HF therapy was not associated with an increased risk of 30-day all-cause mortality or re-admission. Longer time to first IV HF therapy was associated 
with modest but statistically significant increases in both index admission mortality rate and length of stay.
